Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eculizumab Phase 2/3 Study in Japan
jRCT2080225194Phase 3Recruiting
- Start
- May 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3 trial of eculizumab. Started May 2020; status: recruiting.
02
Drugs
eculizumab
Beyond the preview
Go deeper on jRCT2080225194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225194.